-
Long-Term Treatment Duration and Safety of Axatilimab Among Patients With Chronic Graft-Versus-Host Disease in AGAVE-201
-
Revumenib for Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia: Outcomes by Leukemia Type in the Phase 2 AUGMENT-101 Study 1001
-
Real-World Treatment Patterns and Outcomes among Patients with Newly Diagnosed NPM1-Mutated Acute Myeloid Leukemia in the United States
-
Phase II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in Newly Diagnosed AML
-
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed Older Adults with Acute Myeloid Leukemia (AML) and NPM1 mutation or KMT2A rearrangement: Updated Results from the Beat AML Consortium
-
Revumenib as maintenance for AML following allogeneic stem cell transplantation.